A multiregional, randomized, controlled, open-label, phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Trial in progress.
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Institutions: Peking University Cancer Hospital, National Cancer Center Hospital East, Shandong Tumor Hospital, Nanjing Drum Tower Hospital, First Affiliated Hospital of Fujian Medical University, Ningxia Medical University, Ningxia Medical University General Hospital, Shanxi Provincial Cancer Hospital, Third Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Wannan Medical College, Henan Cancer Hospital, Fujian Provincial Cancer Hospital, Hunan Cancer Hospital, Hubei Cancer Hospital, West China Hospital of Sichuan University, Sichuan Cancer Hospital, Hubei University of Arts and Science, Xiangyang Central Hospital, Innovent Biologics (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Innovent Biologics
OpenAlex ID: W4410814967